News

The study, published in The American Journal of Managed Care, suggests that this approach may help quickly identify those patients most likely to benefit from medication adherence interventions.

All rights and licenses granted to Richter have terminated and reverted back to Palatin. There are no payment or reimbursement obligations as a result of the license agreement

The new outstation is located on the Bayer HealthCare campus, within the CoLaborator building that is rented out by Bayer to smaller companies and start-ups. NMI TT Pharmaservices

The study reported today in Proceedings of the National Academy of Sciences breathes new life into the field of targeted delivery, the ongoing effort to fashion treatments that

The druggability of two kinase targets in a specific genetic context is being validated by the two companies as part of the original alliance started in September 2013.

ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will provide up to a total of $38 million over the next 23 months to support development as well as

The DREAM Challenge is an open innovation non-profit biology project in which scientists share ideas and data. AstraZeneca’s move is aimed at advancing research into combination cancer therapy

The new biotechnology, dubbed the Cybercyte, is designed to cut in half the time and money required for preclinical trials. Cytocybernetics claims that the new technology could rapidly

The company will use the grant to discover preclinical DUB inhibitors directed at specific deubiquitylating enzymes (DUBs), which are involved in several cellular processes, including DNA damage and